Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B
Julianne Bayliss, Lilly Yuen, Gillian Rosenberg, Darren Wong, Margaret Littlejohn, Kathleen Jackson, Anuj Gaggar, Kathryn M Kitrinos, G Mani Subramanian, Patrick Marcellin, Maria Buti, Harry LA Janssen, Ed Gane, Vitina Sozzi, Danni Colledge, Rachel Hammond, Rosalind Edwards, Stephen Locarnini, Alexander Thompson, Peter A Revill
Gut | BMJ PUBLISHING GROUP | Published : 2017
LY, JB, KJ, SB and PAR have received grant/research support from Gilead; AG, KMK and GMS are employees of and own stock in Gilead; SL is an advisor for Gilead and BMS; PM is an advisor for Abbott, Boehringer Ingelheim, BMS, Gilead, Janssen/Tibotec, Merck, Norvartis, Pfizer, Roche and Vertex; AT is an advisor for and has received grant/research support from Merck, Janssen/Tibotec, Gilead and Roche and speaker's fees from Merck, Roche and BMS. PAR is currently in receipt of a Royal Melbourne Hospital Keir Research Fellowship.